Abstract: The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

Abstract: The present invention pertains to a vaccine comprising inactivated Lawsonia intracellularis antigen for intradermal administration to an animal that has maternally derived antibodies directed against Lawsonia intracellularis, for use in a method to protect the animal against a disorder arising from an infection with Lawsonia intracellularis.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

Abstract: Porcine pestivirus designated herein as atypical porcine pestivirus (“APPV”) (Genbank accession no. KR011347.1). Immunogenic compositions to induce an immune response against porcine pestivirus infection in a pig are described, which APPV antigenic agents (e.g., isolated whole virus, derivatives thereof, functional fragments thereof, and combinations of the foregoing). Methods of vaccinating against porcine pestivirus infection using the immunogenic compositions are also described. The methods can be also applied for clinical research and/or study, including diagnostic methods for detecting pestivirus infection using monoclonal antibodies specifically binding to APPV epitopes.

Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.

Abstract: The invention provides an isolated H7 influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.

Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.

Abstract: Provided are immunomodulatory pharmaceutical compositions that include alpha-synuclein, and at least one preselected antigen, such as at least one preselected peptide antigen or immunogen. Also provided are methods for modulating immune activity toward at least one preselected antigen in an at least substantially antigen-specific manner that includes administering such a composition to a human patient or a non-human mammalian subject.

Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.

Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

Abstract: Disclosed herein, are compositions comprising one or more therapeutic agents non-covalently conjugated to a nanomaterial (e.g., graphene oxide). Also, described herein, are methods of preparing stable compositions, the methods comprising a plurality of antibodies non-covalently bound to graphene oxide; physiologically acceptable compositions including them; and methods of administering the compositions to patients for the treatment of a disease such as cancer and autoimmune disorders as well as for the prevention of graft rejection.

Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.

Abstract: The present disclosure relates to the modulation of cell activity by sequential release of several biomolecule from a given nanocarrier using a given wavelength. The present disclosure describes a composition for controlled release of biomolecules comprising: a gold nanoparticle; at least two different biomolecules; at least two different oligonucleotides having different melting points, binding said biomolecules to the surface of the gold nanoparticle; wherein the binding is obtainable via hybridization of complementary oligonucleotides; wherein each of the oligonucleotides is a photo-active such that the respective biomolecule is releasable by photo-activation. The composition of the present disclosure may be use in medicine, namely in the treatment of cancer, aging diseases, and accelerated aging syndromes, infectious diseases such as AIDS, epigenetic diseases such as polycystic ovary syndrome, or cardiac diseases, such as cardiac regeneration.

Abstract: A process for treating glaucoma whereby the treatment can be accomplished by the use of medication or by surgery, or both, in order to control or prevent the occurrence of glaucoma. The optic nerve is aligned within and between two distinct pressurized spaces and within the dural sheath, the intraocular space and the intracranial space having an intraocular pressure (IOP) and an intracranial pressure (ICP), respectively. Medicine can be administered to raise the intracranial pressure in order to reach a desirable lower translaminar pressure difference across these two pressurized spaces which are separated by the lamina cribrosa in order to treat glaucoma. An alternate closely related mode of the treatment process is the implanting of a shunt substantially between the intraocular space and the intracranial space in order to beneficially equalize pressure differentials across the intraocular space and the intracranial space.

Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.

Abstract: Provided are compositions and methods for producing a lipidic film. The method comprises the steps of: (i) dissolving a lipid mix in isopropanol to form a homogeneous mix; and (ii) removing the solvent from the homogeneous mix to form a lipidic film, wherein the lipid mix comprises a lipid and cholesterol.

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.

Abstract: In the present invention, gelled polymeric compositions for controlled release are described, which admit the incorporation of a range of chemical, pharmaceutical or food substances, in order to be a transport towards the gastrointestinal tract. The gelled polymeric compositions as described in the invention are used as the basis for the preparation of, for example: excipients, vehicles, coatings, films, hydrogels, among others, thus being highly profitable for the development of products for the pharmaceutical industry and/or the food industry.

Abstract: The most prevalent pharmaceutical dosage forms at present, the oral-delivery tablets, are granular solids. An inherent limitation of such granular solids for drug release applications is the unpredictability of the microstructure. As a result, the drug release rate and other properties are difficult to control, and their range is also limited. Presented herein, therefore, is a solid dosage form with predictable microstructure and properties. The dosage form includes a drug-containing solid comprising a three dimensional structural framework of one or more two-dimensional structural elements.

Abstract: mRNA polymer complexes and drug delivery systems are disclosed herein that include a cationic polymer electrostatically complexed to an mRNA molecule that encodes a desired protein. Also disclosed herein are methods of treating as well as methods of slowing the loss of, increasing, and/or maintaining lean muscle mass in a subject, such as using mRNA polymer complexes and drug delivery systems.

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

Abstract: The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.

Abstract: The present invention discloses a water-soluble docetaxel anticancer drug compound having the structure of Formula I below: in which R=—CH3, —CH2CH3, —CH2CH2CH3, or —CH2CH2CH2CH3; and n=5-500. The active moiety docetaxel in the anticancer drug compound is covalently conjugated to a polyethylene glycol monoalkyl ether through a linker diglycoloyl (carbonyl methoxyacetyl) to form the water-soluble docetaxel anticancer drug compound. The present invention also relates to a preparation method of the drug compound and use thereof.

Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Abstract: The invention relates generally to antibodies that bind CD147, activatable antibodies that bind to CD147 and methods of making and using these antibodies and activatable antibodies in a variety of therapeutic, prophylactic, and diagnostic contexts. In some embodiments, the CD147 antibodies and CD147 activatable antibodies bind human and cynomolgus monkey CD147.

Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds AXL, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Abstract: Provided are a stem cell-nano anticancer drug complex in which an anticancer drug based on carbon nanotubes (CNT) and gold (Au) nano particles is loaded on the surface of stem cells, which can overcome side effects of conventional stem cells and targeting limitations of nano anticancer drugs and whose anticancer effect is very excellent, the use thereof, and a method for preparing the same.

Abstract: Disclosed herein are compositions and nanoconjugates comprising a micelle construct; an antibody single chain fragment variable (scFv); a NF-kb inhibitor; and a topoisomerase II inhibitor. Further disclosed herein are methods of delivering a drug molecule to a tumor site of a subject comprising: attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and delivering the drug molecule attached to the targeted micelle to the tumor site through intracellular delivery. Also disclosed herein are methods of treating cancer or inhibiting tumor cell growth comprising administering to a subject in need thereof, a therapeutically effective dosage of a composition comprising a micelle construct, an antibody single chain fragment variable (say), a NF-kb inhibitor, and a topoisomerase II inhibitor.

Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.

Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.

Abstract: The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IX? reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.

Abstract: Provided is a nanophosphor having a core/double shell structure, the nanophosphor including a upconversion core including a Yb3+, Ho3+, and Ce3+? co-doped fluoride-based nanophosphor represented by Formula 1; a first shell surrounding at least a portion of the upconversion core, and comprising a Nd3+ and Yb3+ co-doped fluoride-based crystalline composition represented by Formula 2; and a second shell surrounding at least a portion of the first shell, and having paramagnetic properties represented by Formula 3.

Abstract: The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.

Abstract: A sterilization apparatus for use with a cardioplegia heat exchanger device includes an enclosure having an internal volume defined between two ends and a wall. The first end includes a bulb access port, an inlet port formed proximate to or in the first end, a biofilm sterilizing port, and an outlet port formed proximate to or in the second end. A quartz sleeve and an ultraviolet bulb project inwardly into the internal volume from proximate the bulb access port. The ultraviolet bulb illuminates to radiate water entering the inlet port and flowing towards the outlet port between the cylindrical wall and the quartz sleeve. A wiper ring may be slidably fixed around the quartz sleeve for cleaning. In an alternate embodiment, the bulb access port is formed through a water tank of the cardioplegia heat exchanger device with the quartz sleeve and bulb projecting inwardly into the water tank.

Abstract: A disposable antiseptic wipe apparatus includes a bacteria-proof packaging container having an interior compartment. An antiseptic wipe is infused with an antiseptic material and positioned within the interior compartment. The antiseptic wipe has a rolled cylindrical shape. A portion of packaging container is removable from the antiseptic wipe to exposed one end of the rolled, cylindrical shape of the antiseptic wipe while an unexposed end of the rolled, cylindrical shape of the antiseptic wipe is graspable by a user through the packaging container.

Abstract: Disclosed is a coating composition for preventing odor. The coating composition may include one or more types of odorless microorganisms selected from the group consisting of Caulobacter vibrioides, Bradyrhizobium diazoefficiens, Bradyrhizobium daqingense and Methylobacterium brachiatum or a culture solution thereof. Further provided is a method for preventing odor, and the method may include applying the coating composition for preventing odor. When a biofilm is formed from the microorganisms in the coating composition by coating an object on which an odor-causing microorganism can live, the inflow and the inhabitation of external microorganisms generating odor may be significantly blocked, thereby enabling odor to be effectively prevented.

Abstract: [Object] To propose a novel and improved fragrance providing device that can be reduced in size. [Solution] Provided is a fragrance providing device including: a fragrance material holding member in which a plurality of holding passages each holding a fragrance material are provided to penetrate the fragrance material holding member; and a rotation mechanism capable of relatively rotating the fragrance material holding member and a member provided with an introduction port that communicates with part of the plurality of holding passages and introduces air supplied from an airflow source to the part of the holding passages, in a manner that the part of the holding passages that communicates with the introduction port is switched.

Abstract: A system, unit, device and method are shown for providing substantially simultaneous disinfection of bacteria or other pathogens in air passing through the system using C-band ultraviolet radiation from an ultraviolet light source and that is also capable of substantially simultaneous and efficient disinfecting air and surfaces outside the device using the same ultraviolet light source.

Abstract: An improved fibrinogen-based tissue sealing patch having a degradation time of less than two weeks is disclosed. The patch comprises a polyethylene glycol-caprolactone-lactide (PEG-CL-LA) triblock copolymer film into which a fibrinogen-based sealant comprising less than 8 mg/cm2 fibrinogen and less than 10 IU/cm2 thrombin has been incorporated. In preferred embodiments, the polymer film comprises PEG having a molecular weight of between 3000 and 3500 and a CL:LA:PEG ratio of 34:2:1. Methods of production and use of the patch are also disclosed.

Abstract: A device for application onto wounds with a liquid rapidly polymerizable adhesive for forming skin closure systems, comprising a thin flexible flat porous tape, preferably a mesh, elongated along a longitudinal axis and having a lower side or wound-facing side and an opposing upper side, a periphery, and central portion in immediate vicinity of the axis; said tape coated or impregnated with an initiator or accelerator of polymerization; said tape having a plurality of elongated traces of soluble pressure sensitive adhesive (PSA) disposed on the wound-facing side; said traces covering from about 3% to about 50% of area of said tape and extending from the periphery to the central portion of said tape.

Abstract: A method for making water-absorbing polymer particles is provided and includes a first aqueous polymerization solution including crosslinkers, polymerizable monomers and/or oligomers and inorganic solid particles, and a second aqueous solution including inorganic solid particles, crosslinkers and either polymerizable monomers and/or oligomers, or crosslinkable polymers.

Abstract: Provided, among other things, is a method of treating skin and soft tissue wounds, ulcers, burns, various types of dermatoses, inflammatory conditions of the mucosa, and the like comprising: periodically applying to the wound, inflammatory condition of mucosal tissues, or dermatoses, over a course of day an effective amount of water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.

Abstract: The present disclosure relates to a composition of an engineered biomaterial including extracellular matrix components of a mammalian tissue and a polymer; method of wound healing; and methods delivering therapeutic agents, growth factors, or hydration for wound healing to a subject in need thereof.

Abstract: Absorbable iron-based alloy implanted medical device and manufacturing method thereof. The iron-based alloy implanted medical device comprises an iron-based alloy substrate (11), a degradable polymer layer (13) disposed on a surface of the iron-based alloy substrate (11), and a tannic acid chemical conversion film (12) disposed on a surface of the iron-based alloy substrate (11). After the medical device is implanted into a body, the tannic acid chemical conversion film (12) is configured to protect the iron-based alloy substrate (11) coated thereby from being in contact with a body fluid, thereby ensuring that the device meets a clinical mechanical property requirement in the early stage of implantation. Furthermore, the iron-based alloy implanted medical device has a decreased size, and produces a decreased amount of a corrosive product after being implanted, facilitating faster absorption or elimination of the corrosive product.